NCT03696953View on ClinicalTrials.gov

The Efficacy of Probiotics to Reduce Antepartum Group B Streptococcus Colonization.

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

109

Participants

Timeline

Start Date

February 1, 2019

Primary Completion Date

September 30, 2022

Study Completion Date

September 30, 2024

Conditions
Group B Streptococcus Carrier in ChildbirthGastrointestinal Symptoms
Interventions
BIOLOGICAL

Florajen3

Probiotic combination product One capsule daily by mouth.

Trial Locations (1)

53233

Aurora Sinai Medical Center, Milwaukee

All Listed Sponsors
collaborator

Wake Forest University Health Sciences

OTHER

collaborator

University of Wisconsin, Madison

OTHER

lead

Marquette University

OTHER

NCT03696953 - The Efficacy of Probiotics to Reduce Antepartum Group B Streptococcus Colonization. | Biotech Hunter | Biotech Hunter